MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) Net margin 2016–2024
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) net profit margin by fiscal year — reported net income divided by reported revenue.
-2212.7%FY2024 · since FY2016: -3906.9% → -2212.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -2212.7% | -1493.0 pp |
| FY2023 | -719.6% | +62907.6 pp |
| FY2022 | -63627.3% | -48922.2 pp |
| FY2021 | -14705.1% | +10288.1 pp |
| FY2020 | -24993.1% | -10485.7 pp |
| FY2019 | -14507.4% | -5099.1 pp |
| FY2018 | -9408.3% | — |
| FY2016 | -3906.9% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More MTNB financial trends
MTNB RevenueMTNB Net incomeMTNB Gross profitMTNB Gross marginMTNB Operating incomeMTNB Operating marginMTNB Operating cash flowMTNB Free cash flowMTNB Capital expendituresMTNB Return on equityMTNB Stock buybacksMTNB Dividends paidMTNB Total assetsMTNB Total liabilitiesMTNB Shareholders’ equityMTNB overview →